Simona Soverini

List of Publications by Citations

296 papers	10,250 citations	48 h-index	98 g-index
328 ext. papers	11,737 ext. citations	4.2 avg, IF	5.38 L-index

#	Paper	IF	Citations
296	European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. *Blood*, **2013**, 122, 872-84	2.2	1413
295	Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. *Blood*, **2006**, 108, 28-37	2.2	977
294	Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. *Clinical Cancer Research*, **2006**, 12, 7374-9	12.9	405
293	BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. *Blood*, **2011**, 118, 1208-15	2.2	395
292	European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. *Leukemia*, **2020**, 34, 966-984	10.7	356
291	Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. *Blood*, **2011**, 118, 6521-8	2.2	312
290	ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. *Journal of Clinical Oncology*, **2005**, 23, 4100-9	2.2	308
289	Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. *Journal of Clinical Oncology*, **2009**, 27, 4204-10	2.2	248
288	IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report. *Journal of Clinical Oncology*, **2009**, 27, 5202-7	2.2	245
287	BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. *Cancer Cell*, **2014**, 26, 428-442	24.3	233
286	Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP). *Blood*, **2009**, 114, 2159-67	2.2	180
285	The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study. *Haematologica*, **2007**, 92, 1173-9	6.6	177
284	Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. *Blood*, **2009**, 114, 4933-8	2.2	176
283	BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships. *Blood*, **2013**, 121, 489-98	2.2	154
282	Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. *Haematologica*, **2007**, 92, 401-4	6.6	150
281	Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. *Blood*, **2009**, 114, 2168-71	2.2	133
280	Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain. *Blood*, **2013**, 122, 1634-48	2.2	127

279	Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. *Journal of Clinical Oncology* , **2004**, 22, 2654-61	2.2	123
278	Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib. *Clinical Chemistry*, **2004**, 50, 1205-13	5.5	109
277	Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy. *Molecular Cancer*, **2018**, 17, 49	42.1	103
276	Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation. *Blood*, **2003**, 102, 1588-94	2.2	100
275	Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia. *Leukemia Research*, **2014**, 38, 10-20	2.7	97
274	Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance. *Blood*, **2008**, 112, 3847-55	2.2	95
273	Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement. *Cancer*, **2014**, 120, 1002-9	6.4	92
272	Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation. *Blood*, **2009**, 114, 5271-8	2.2	87
271	Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia. *Blood*, **2004**, 104, 4245-51	2.2	85
270	Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy. *Haematologica*, **2013**, 98, 193-200	6.6	83
269	Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib. *Journal of Clinical Oncology*, **2012**, 30, 4323-9	2.2	78
268	Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. *Clinical Cancer Research*, **2006**, 12, 3037-42	12.9	78
267	Chronic myeloid leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Annals of Oncology*, **2012**, 23 Suppl 7, vii72-7	10.3	71
266	Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients. *Blood*, **2016**, 127, 703-12	2.2	65
265	Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib. *Leukemia*, **2015**, 29, 1823-31	10.7	64
264	A polymorphism in the chromosome 9p21 ANRIL locus is associated to Philadelphia positive acute lymphoblastic leukemia. *Leukemia Research*, **2011**, 35, 1052-9	2.7	64
263	Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis. *Haematologica*, **2011**, 96, 552-7	6.6	64
262	Antileukemia effects of xanthohumol in Bcr/Abl-transformed cells involve nuclear factor-kappaB and p53 modulation. *Molecular Cancer Therapeutics*, **2008**, 7, 2692-702	6.1	63

261	IKAROS deletions dictate a unique gene expression signature in patients with adult B-cell acute lymphoblastic leukemia. *PLoS ONE*, **2012**, 7, e40934	3.7	60
260	Molecular response to imatinib in late chronic-phase chronic myeloid leukemia. *Blood*, **2004**, 103, 2284-90	9.2	60
259	Dual tyrosine kinase inhibitors in chronic myeloid leukemia. *Leukemia*, **2005**, 19, 1872-9	10.7	58
258	Response definitions and European Leukemianet Management recommendations. *Best Practice and Research in Clinical Haematology*, **2009**, 22, 331-41	4.2	56
257	Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase. *Journal of Cancer Research and Clinical Oncology*, **2015**, 141, 887-99	4.9	54
256	Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party. *Blood*, **2009**, 113, 3428-34	2.2	53
255	The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib. *American Journal of Hematology*, **2017**, 92, 797-805	7.1	52
254	CDKN2A/B alterations impair prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia patients. *Clinical Cancer Research*, **2011**, 17, 7413-23	12.9	52
253	Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia. *Journal of Clinical Oncology*, **2006**, 24, e51-2	2.2	52
252	The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview. *Leukemia*, **2019**, 33, 1173-1183	10.7	51
251	Chromothripsis in acute myeloid leukemia: biological features and impact on survival. *Leukemia*, **2018**, 32, 1609-1620	10.7	50
250	Mutations in the BCR-ABL1 Kinase Domain and Elsewhere in Chronic Myeloid Leukemia. *Clinical Lymphoma, Myeloma and Leukemia*, **2015**, 15 Suppl, S120-8	2	49
249	Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party. *Haematologica*, **2007**, 92, 101-5	6.6	49
248	Treatment and monitoring of Philadelphia chromosome-positive leukemia patients: recent advances and remaining challenges. *Journal of Hematology and Oncology*, **2019**, 12, 39	22.4	48
247	Differences among young adults, adults and elderly chronic myeloid leukemia patients. *Annals of Oncology*, **2015**, 26, 185-192	10.3	48
246	Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib. *Haematologica*, **2012**, 97, 907-14	6.6	48
245	Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias. *Blood*, **2011**, 118, 5697-700	2.2	40
244	Protein tyrosine phosphatase receptor type {gamma} is a functional tumor suppressor gene specifically downregulated in chronic myeloid leukemia. *Cancer Research*, **2010**, 70, 8896-906	10.1	40

243	Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML. *Journal of Clinical Oncology*, **2008**, 26, 106-11	2.2	40
242	Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP. *Blood Advances*, **2019**, 3, 4280-4290	7.8	40
241	The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis. *Haematologica*, **2013**, 98, 1510-6	6.6	39
240	The PAX5 gene is frequently rearranged in BCR-ABL1-positive acute lymphoblastic leukemia but is not associated with outcome. A report on behalf of the GIMEMA Acute Leukemia Working Party. *Haematologica*, **2010**, 95, 1683-90	6.6	39
239	Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients. *Oncotarget*, **2016**, 7, 21982-90	3.3	39
238	c-MYC oncoprotein dictates transcriptional profiles of ATP-binding cassette transporter genes in chronic myelogenous leukemia CD34+ hematopoietic progenitor cells. *Molecular Cancer Research*, **2011**, 9, 1054-66	6.6	37
237	Imatinib mesylate for the treatment of chronic myeloid leukemia. *Expert Review of Anticancer Therapy*, **2008**, 8, 853-64	3.5	37
236	Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study. *Blood*, **2020**, 135, 534-541	2.2	37
235	Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia. *Blood*, **2013**, 121, 5138-44	2.2	36
234	Identification of different Ikaros cDNA transcripts in Philadelphia-positive adult acute lymphoblastic leukemia by a high-throughput capillary electrophoresis sizing method. *Haematologica*, **2008**, 93, 1814-21	6.6	34
233	Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment. *Journal of Clinical Oncology*, **2006**, 24, 454-9	2.2	34
232	Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL. *Lancet Oncology, The*, **2007**, 8, 273-4	21.7	34
231	ABCB1 polymorphisms predict imatinib response in chronic myeloid leukemia patients: a systematic review and meta-analysis. *Pharmacogenomics Journal*, **2015**, 15, 127-34	3.5	33
230	Choosing the best second-line tyrosine kinase inhibitor in imatinib-resistant chronic myeloid leukemia patients harboring Bcr-Abl kinase domain mutations: how reliable is the IC? *Oncologist*, **2011**, 16, 868-76	5.7	33
229	Bellerophontes: an RNA-Seq data analysis framework for chimeric transcripts discovery based on accurate fusion model. *Bioinformatics*, **2012**, 28, 2114-21	7.2	33
228	Best Practices in Chronic Myeloid Leukemia Monitoring and Management. *Oncologist*, **2016**, 21, 626-33	5.7	31
227	Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients. *American Journal of Hematology*, **2016**, 91, 692-9	7.1	31
226	Mechanisms of Disease Progression and Resistance to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: An Update. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	30

225	Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia. *Haematologica*, **2015**, 100, 1146-50	6.6	29
224	Real-time quantification of different types of bcr-abl transcript in chronic myeloid leukemia. *Haematologica*, **2001**, 86, 252-9	6.6	29
223	Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr-Abl mutations and mutational analysis. *Pharmacogenomics*, **2012**, 13, 1271-84	2.6	28
222	Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical management. *Hematological Oncology*, **2006**, 24, 196-204	1.3	28
221	Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response. *Clinical Cancer Research*, **2009**, 15, 1059-63	12.9	27
220	Pancreatic enzyme elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure. *Haematologica*, **2009**, 94, 1758-61	6.6	26
219	Polymerase chain reaction-based detection of minimal residual disease in multiple myeloma patients receiving allogeneic stem cell transplantation. *Haematologica*, **2000**, 85, 930-4	6.6	25
218	c-Abl and Src-family kinases cross-talk in regulation of myeloid cell migration. *FEBS Letters*, **2010**, 584, 15-21	3.8	23
217	Rapid detection of Flt3 mutations in acute myeloid leukemia patients by denaturing HPLC. *Clinical Chemistry*, **2003**, 49, 1642-50	5.5	23
216	The impact of sensitive KIT D816V detection on recognition of indolent Systemic Mastocytosis. *Leukemia Research*, **2015**, 39, 273-8	2.7	22
215	Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment. *Blood Cancer Journal*, **2015**, 5, e347	7	22
214	A population-based study of chronic myeloid leukemia patients treated with imatinib in first line. *American Journal of Hematology*, **2017**, 92, 82-87	7.1	22
213	Different isoforms of the B-cell mutator activation-induced cytidine deaminase are aberrantly expressed in BCR-ABL1-positive acute lymphoblastic leukemia patients. *Leukemia*, **2010**, 24, 66-73	10.7	22
212	Chronic myeloid leukemia: the concepts of resistance and persistence and the relationship with the BCR-ABL1 transcript type. *Leukemia*, **2019**, 33, 2358-2364	10.7	21
211	WT1 transcript amount discriminates secondary or reactive eosinophilia from idiopathic hypereosinophilic syndrome or chronic eosinophilic leukemia. *Leukemia*, **2007**, 21, 1442-50	10.7	21
210	IDH2 somatic mutations in chronic myeloid leukemia patients in blast crisis. *Leukemia*, **2011**, 25, 178-81	10.7	20
209	Prediction of response to imatinib by prospective quantitation of BCR-ABL transcript in late chronic phase chronic myeloid leukemia patients. *Annals of Oncology*, **2006**, 17, 495-502	10.3	20
208	Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients. *Haematologica*, **2016**, 101, 1200-1207	6.6	19

207	Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper. *Journal of Hematology and Oncology*, **2019**, 12, 131	22.4	19
206	SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis. *Leukemia*, **2018**, 32, 139-148	10.7	17
205	Use of a high sensitive nanofluidic array for the detection of rare copies of BCR-ABL1 transcript in patients with Philadelphia-positive acute lymphoblastic leukemia in complete response. *Leukemia Research*, **2014**, 38, 581-5	2.7	17
204	Intermittent targeting as a tool to minimize toxicity of tyrosine kinase inhibitor therapy. *Nature Clinical Practice Oncology*, **2009**, 6, 68-9		15
203	In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants. *BMC Cancer*, **2016**, 16, 572	4.8	15
202	Line Treatment of Adult Ph+ Acute Lymphoblastic Leukemia (ALL) Patients. Final Results of the GIMEMA LAL1205 Study. *Blood*, **2008**, 112, 305-305	2.2	14
201	Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: molecular cytogenetic characterization and influence on TKIs therapy. *Oncotarget*, **2017**, 8, 29906-29913	3.3	14
200	Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia. *BMC Cancer*, **2013**, 13, 173	4.8	13
199	Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia. *Haematologica*, **2017**, 102, 1530-1536	6.6	12
198	Long term outcome of Ph+ CML patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib era. *American Journal of Hematology*, **2014**, 89, 119-24	7.1	12
197	Molecular monitoring and mutations in chronic myeloid leukemia: how to get the most out of your tyrosine kinase inhibitor. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2014**, 167-75	7.1	12
196	Understanding the role of mutations in therapeutic decision making for chronic myeloid leukemia. *Seminars in Hematology*, **2009**, 46, S22-6	4	12
195	Excellent Outcomes at 3 Years with Nilotinib 800 Mg Daily In Early Chronic Phase, Ph+ Chronic Myeloid Leukemia (CML): Results of a Phase 2 GIMEMA CML WP Clinical Trial. *Blood*, **2010**, 116, 359-359	2.2	12
194	Interferon-Revisited: Individualized Treatment Management Eased the Selective Pressure of Tyrosine Kinase Inhibitors on BCR-ABL1 Mutations Resulting in a Molecular Response in High-Risk CML Patients. *PLoS ONE*, **2016**, 11, e0155959	3.7	12
193	Present and future of molecular monitoring in chronic myeloid leukaemia. *British Journal of Haematology*, **2016**, 173, 337-49	4.5	12
192	Clinical impact of low-burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patients. *Leukemia*, **2016**, 30, 1615-9	10.7	11
191	BCR-ABL1-associated reduction of beta catenin antagonist Chibby1 in chronic myeloid leukemia. *PLoS ONE*, **2013**, 8, e81425	3.7	11
190	Nilotinib restores long-term full-donor chimerism in Ph-positive acute lymphoblastic leukemia relapsed after allogeneic transplantation. *Bone Marrow Transplantation*, **2009**, 44, 263-4	4.4	11

189	New targets for Ph+ leukaemia therapy. *Best Practice and Research in Clinical Haematology*, **2009**, 22, 445-54	4.2	11
188	CML Patients with Low OCT-1 Activity Achieve Better Molecular Responses on High Dose Imatinib Than on Standard Dose. Those with High OCT-1 Activity Have Excellent Responses on Either Dose: A TOPS Correlative Study. *Blood*, **2008**, 112, 3187-3187	2.2	11
187	Novel and Rare Fusion Transcripts Involving Transcription Factors and Tumor Suppressor Genes in Acute Myeloid Leukemia. *Cancers*, **2019**, 11,	6.6	11
186	Novel mutation and RNA splice variant of fibroblast growth factor receptor 3 in multiple myeloma patients at diagnosis. *Haematologica*, **2002**, 87, 1036-40	6.6	11
185	Recent Advances in the Molecular Biology of Systemic Mastocytosis: Implications for Diagnosis, Prognosis, and Therapy. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	10
184	Impact of SLC22A1 and CYP3A5 genotypes on imatinib response in chronic myeloid leukemia: A systematic review and meta-analysis. *Pharmacological Research*, **2018**, 131, 244-254	10.2	10
183	Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance. *Biologics: Targets and Therapy*, **2007**, 1, 121-7	4.4	10
182	Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia. *American Journal of Hematology*, **2016**, 91, 617-22	7.1	10
181	Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors. *Journal of Experimental and Clinical Cancer Research*, **2019**, 38, 216	12.8	9
180	Molecular monitoring. *Current Hematologic Malignancy Reports*, **2014**, 9, 1-8	4.4	9
179	Molecular response in CML: where is the bar?. *Blood*, **2014**, 124, 469-71	2.2	9
178	Monitoring BCR-ABL transcript levels by real-time quantitative polymerase chain reaction: a linear regression equation to convert from BCR-ABL/B2M ratio to estimated BCR-ABL/ABL ratio. *Haematologica*, **2007**, 92, 429-30	6.6	9
177	Molecular therapy for multiple myeloma. *Haematologica*, **2001**, 86, 908-17	6.6	9
176	FOXM1 Transcription Factor: A New Component of Chronic Myeloid Leukemia Stem Cell Proliferation Advantage. *Journal of Cellular Biochemistry*, **2017**, 118, 3968-3975	4.7	8
175	Advances in the biology and therapy of chronic myeloid leukemia: proceedings from the 6th Post-ASH International Chronic Myeloid Leukemia and Myeloproliferative Neoplasms Workshop. *Leukemia and Lymphoma*, **2013**, 54, 1151-8	1.9	8
174	14-3-3 Binding and Sumoylation Concur to the Down-Modulation of Ecatenin Antagonist chibby 1 in Chronic Myeloid Leukemia. *PLoS ONE*, **2015**, 10, e0131074	3.7	8
173	Characterization of 46 patient-specific BCR-ABL1 fusions and detection of SNPs upstream and downstream the breakpoints in chronic myeloid leukemia using next generation sequencing. *Molecular Cancer*, **2015**, 14, 89	42.1	8
172	Molecular monitoring of acute myeloid leukemia associated with inv(16): threshold of CBFbeta/MYH11 transcript copy number above which relapse occurs and below which continuous Complete Remission is likely. *Leukemia*, **2003**, 17, 650-1; author reply 651-2	10.7	8

171	Responses and Disease Progression in CML-CP Patients Treated with Nilotinib after Imatinib Failure Appear To Be Affected by the BCR-ABL Mutation Status and Types.. *Blood*, **2007**, 110, 320-320	2.2	8
170	New mechanisms of resistance in Philadelphia chromosome acute lymphoblastic leukemia. *Expert Review of Hematology*, **2009**, 2, 297-303	2.8	7
169	Application of the whole-transcriptome shotgun sequencing approach to the study of Philadelphia-positive acute lymphoblastic leukemia. *Blood Cancer Journal*, **2012**, 2, e61	7	7
168	Early CP CML, Nilotinib 400 mg Twice Daily Frontline: Beyond 3 Years, Results Remain Excellent and Stable (A GIMEMA CML Working Party Trial). *Blood*, **2011**, 118, 2756-2756	2.2	7
167	Prognostic Value of BCR-ABL1 Transcript Type in Chronic Myeloid Leukemia Patients Treated Frontline with Nilotinib. *Blood*, **2016**, 128, 3070-3070	2.2	7
166	Molecular Testing in CML between Old and New Methods: Are We at a Turning Point?. *Journal of Clinical Medicine*, **2020**, 9,	5.1	7
165	The Use of EUTOS Long-Term Survival Score Instead of Sokal Score Is Strongly Advised in Elderly Chronic Myeloid Leukemia Patients. *Blood*, **2018**, 132, 44-44	2.2	6
164	Suppression of Bcr-Abl Expression in CML by A Panel of miRNAs.. *Blood*, **2009**, 114, 854-854	2.2	6
163	Impact Of Baseline (BL) Mutations, Including Low-Level and Compound Mutations, On Ponatinib Response and End Of Treatment (EOT) Mutation Analysis In Patients (Pts) With Chronic Phase Chronic Myeloid Leukemia (CP-CML). *Blood*, **2013**, 122, 652-652	2.2	6
162	The Interlaboratory Robustness Of Next-Generation Sequencing (IRON) Study Phase II: Deep-Sequencing Analyses Of Hematological Malignancies Performed In 8,867 Cases By An International Network Involving 27 Laboratories. *Blood*, **2013**, 122, 743-743	2.2	6
161	Assessment of individual molecular response in chronic myeloid leukemia patients with atypical BCR-ABL1 fusion transcripts: recommendations by the EUTOS cooperative network. *Journal of Cancer Research and Clinical Oncology*, **2021**, 147, 3081-3089	4.9	6
160	Targeting Leukemic Stem Cells in Chronic Myeloid Leukemia: Is It Worth the Effort?. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	6
159	Next-generation sequencing for BCR-ABL1 kinase domain mutations in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position paper. *Cancer Medicine* , **2020**, 9, 2960-2970	4.8	5
158	Low-level Bcr-Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinib. *Leukemia Research*, **2011**, 35, 1527-9	2.7	5
157	Sequential development of mutant clones in an imatinib resistant chronic myeloid leukaemia patient following sequential treatment with multiple tyrosine kinase inhibitors: an emerging problem?. *Cancer Chemotherapy and Pharmacology*, **2009**, 64, 195-7	3.5	5
156	F317L BCR-ABL1 kinase domain mutation associated with a sustained major molecular response in a CML patient on dasatinib. *Leukemia Research*, **2011**, 35, e118-20	2.7	5
155	A Novel 4-anilino-3-quinolinecarbonitrile Dual Src and Abl Kinase Inhibitor (SKI-606) Has In Vitro Activity on CML Ph+Blast Cells Resistant to Imatinib.. *Blood*, **2004**, 104, 1991-1991	2.2	5
154	Philadelphia Chromosome-Positive Leukemia Patients Who Harbor Imatinib-Resistant Mutations Have a Higher Likelihood of Developing Additional Mutations Associated with Resistance to Novel Tyrosine Kinase Inhibitors.. *Blood*, **2007**, 110, 322-322	2.2	5

153	INCB84344-201: Ponatinib and steroids in frontline therapy of unfit patients with Ph+ acute lymphoblastic leukemia. *Blood Advances*, **2021**,	7.8	5
152	Serum total tryptase level confirms itself as a more reliable marker of mast cells burden in mast cell leukaemia (aleukaemic variant). *Case Reports in Hematology*, **2015**, 2015, 737302	0.7	4
151	Four-channel asymmetric Real-Time PCR hybridization probe assay: a rapid pre-screening method for critical BCR-ABL kinase domain mutations. *Clinical Biochemistry*, **2012**, 45, 345-51	3.5	4
150	Interferon-alpha may restore sensitivity to tyrosine-kinase inhibitors in Philadelphia chromosome positive acute lymphoblastic leukaemia with F317L mutation. *British Journal of Haematology*, **2009**, 146, 227-30	4.5	4
149	Coding sequence and intron-exon junctions of the c-myb gene are intact in the chronic phase and blast crisis stages of chronic myeloid leukemia patients. *Leukemia Research*, **2007**, 31, 163-7	2.7	4
148	First case of an AIDS patient with systemic mast cell disease associated with FIP1-positive eosinophilia treated with imatinib mesylate therapy. *Journal of Clinical Oncology*, **2006**, 24, e6-7	2.2	4
147	Resistance to Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Leukemias: Which Mutations Matter?. *Clinical Leukemia*, **2007**, 1, 223-228		4
146	Mutations at Residues 315 and 317 in the ABL Kinase Domain Are the Main Cause of Resistance to Dasatinib in Philadelphia-Positive (Ph+) Leukemia Patients (pts).. *Blood*, **2006**, 108, 836-836	2.2	4
145	Nilotinib 800 Mg Daily as Frontline Therapy of Ph + Chronic Myeloid Leukemia: Dose Delivered and Safety Profile for the GIMEMA CML Working Party.. *Blood*, **2009**, 114, 2205-2205	2.2	4
144	The BCR-ABL1 Transcript Type Does Not Influence the Response and the Outcome of Chronic Myeloid Leukemia Patients Treated Frontline with Nilotinib. *Blood*, **2012**, 120, 1680-1680	2.2	4
143	Treating Ph+ Acute Lymphoblastic Leukemia (ALL) in the Elderly: The Sequence of Two Tyrosine Kinase Inhibitors (TKI) (Nilotinib and Imatinib) Does Not Prevent Mutations and Relapse.. *Blood*, **2012**, 120, 2601-2601	2.2	4
142	Five-Year Results of Nilotinib 400 Mg BID in Early Chronic Phase Chronic Myeloid Leukemia (CML): High Rate of Deep Molecular Response - Update of the Gimema CML WP Trial CML0307. *Blood*, **2012**, 120, 3784-3784	2.2	4
141	Chibby 1: a new component of β-catenin-signaling in chronic myeloid leukemia. *Oncotarget*, **2017**, 8, 88244-88250	5.3	4
140	Assessing Measurable Residual Disease in Chronic Myeloid Leukemia. BCR-ABL1 IS in the of Molecular Hematology. *Frontiers in Oncology*, **2019**, 9, 863	5.3	3
139	Chromothripsis in acute myeloid leukemia: biological features and impact on survival. *Leukemia*, **2017**,	10.7	3
138	MK-0457: a light at the end of the tunnel?. *Blood*, **2007**, 109, 396-397	2.2	3
137	Abstract 5552: Extremely high rate of complete hematological response of elderly Ph+ acute lymphoblastic leukemia (ALL) patients by innovative sequential use of Nilotinib and Imatinib. A GIMEMA Protocol LAL 1408 **2014**,		3
136	International, Prospective Study Comparing Nilotinib Versus Imatinib with Early Switch to Nilotinib to Obtain Sustained Treatment-Free Remission in Patients with Chronic Myeloid Leukemia. a GIMEMA and HOVON Study. *Blood*, **2018**, 132, 1750-1750	2.2	3

135	Detection of Actionable BCR-ABL1 Kinase Domain (KD) Mutations in Chronic Myeloid Leukemia (CML) Patients with Failure and Warning Response to Tyrosine Kinase Inhibitors (TKIs): Potential Impact of Next-Generation Sequencing (NGS) and Droplet Digital PCR (ddPCR) on Clinical Decision Making. *Blood*, **2019**, 134, 661-661	2.2	3
134	Frequency, Distribution and Prognostic Value of ABL Kinase Domain (KD) Mutations in Different Subsets of Philadelphia-Positive (Ph+) Patients (Pts) Resistant to Imatinib (IM) by the Gimema Working Party on CML.. *Blood*, **2005**, 106, 435-435	2.2	3
133	Gene Expression Profile (GEP) of Chronic Myeloid Leukemia (CML) Patients at Diagnosis: Two Distinguished Subgroups of CML Patients Identified, Based on a Molecular Signature, Irrespective of Their Sokal Risk Score. *Blood*, **2008**, 112, 3190-3190	2.2	3
132	Molecular Response at 3 Months On Nilotinib Therapy Predicts Response and Long-Term Outcomes in Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia in Chronic Phase (CML-CP).. *Blood*, **2009**, 114, 3292-3292	2.2	3
131	Whole-Transcriptome Sequencing In Chronic Myeloid Leukemia Reveals Novel Gene Mutations That May Be Associated with Disease Pathogenesis and Progression. *Blood*, **2010**, 116, 885-885	2.2	3
130	Sensitivity, Reproducibility and Clinical Utility Of Next-Generation Sequencing (NGS) for BCR-ABL1 Kinase Domain Mutation Screening: Results From The CML Work Package Of The Iron-II (Interlaboratory RObustness Of Next-Generation Sequencing) International Study. *Blood*, **2013**,	2.2	3
129	BCR-ABL1 compound mutants: prevalence, spectrum and correlation with tyrosine kinase inhibitor resistance in a consecutive series of Philadelphia chromosome-positive leukemia patients analyzed by NGS. *Leukemia*, **2021**, 35, 2102-2107	10.7	2
128	Ponatinib treatment in chronic myeloid leukemia cell lines targets aurora kinase A/FOXM1 axis. *Hematological Oncology*, **2020**, 38, 201-203	1.3	2
127	A Review and an Update of European LeukemiaNet Recommendations for the Management of Chronic Myeloid Leukemia. *Hematologic Malignancies*, **2016**, 55-69	0	2
126	Aurora kinase inhibitors: which role in the treatment of chronic myelogenous leukemia patients resistant to imatinib?. *Hematology Reports*, **2009**, 1, 1	0.9	2
125	Dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl-positive acute lymphoid leukaemia. *European Journal of Haematology*, **2004**, 72, 302-3	3.8	2
124	Abstract 906:Gas1andKif27genes are strongly up-regulated biomarkers of Hedgehog inhibition (PF-04449913) on leukemia stem cells in Phase I Acute Myeloid Leukemia and Chronic Myeloid Leukemia treated patients **2012**,		2
123	Compound BCR-ABL1 Kinase Domain Mutants: Prevalence, Spectrum and Correlation with Tyrosine Kinase Inhibitor Resistance in a Prospective Series of Philadelphia Chromosome-Positive Leukemia Patients Analyzed By Next Generation Sequencing. *Blood*, **2018**, 132, 789-789	2.2	2
122	Outcome of 472 Chronic Myeloid Leukemia Patients Treated with Frontline Nilotinib: A Gimema CML WP Analysis. *Blood*, **2018**, 132, 458-458	2.2	2
121	Ten-Year Follow-up of Patients with Chronic Myeloid Leukemia Treated with Nilotinib in First-Line: Final Results of the Gimema CML 0307 Trial. *Blood*, **2019**, 134, 4145-4145	2.2	2
120	A New Abl Kinase Inhibitor (AMN107) Has In Vitro Activity on CML Ph+Blast Cells Resistant to Imatinib.. *Blood*, **2004**, 104, 4687-4687	2.2	2
119	A New Abl Kinase Inhibitor (AMN107) Has In Vitro Activity on Chronic Myeloid Leukaemia (CML) Ph+ Cells Resistant to Imatinib.. *Blood*, **2005**, 106, 2004-2004	2.2	2
118	Imatinib Mesylate Can Induce Molecular Complete Remission in Idiopathic Hypereosinophilic Syndrome (HES). A Phase II Multicentric Italian Clinical Trial.. *Blood*, **2005**, 106, 375-375	2.2	2

117	The Presence of the BCR-ABL T315I Mutation In Chronic Phase Chronic Myelogenous Leukemia Resistant to Tyrosine Kinase Inhibitors Profoundly Compromises Overall Survival and Progression Free Survival. Preliminary Results of a Matched Pair Analysis.. *Blood*, **2010**, 116, 3410-3410	2.2	2
116	PF-04449913 Reverts Multi Drug Resistance (MDR) by a Strong Down-Regulation of ABCA2 and BCL2 on Leukemia Stem Cells in Phase I Acute Myeloid Leukemia and Chronic Myeloid Leukemia Treated Patients. *Blood*, **2011**, 118, 1429-1429	2.2	2
115	Gas1 and Kif27 Genes Are Strongly up-Regulated Biomarkers of Hedgehog Inhibition (PF-04449913) on Leukemia Stem Cells in Phase I Acute Myeloid Leukemia and Chronic Myeloid Leukemia Treated Patients. *Blood*, **2011**, 118, 1535-1535	2.2	2
114	Frontline Treatment With Imatinib Mesylate in Chronic Myeloid Leukemia Patients in Early Chronic Phase: a Very Long-Term Analysis by the GIMEMA CML Working Party. *Blood*, **2013**, 122, 258-258	2.2	2
113	Ultra Deep Sequencing (UDS) Allows More Sensitive Detection Of Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL Mutations That Would Influence Therapeutic Decision At The Time Of Switchover To Second- Or Third-Line Therapy. *Blood*, **2013**, 122, 380-380	2.2	2
112	Inactivation of the SETD2 Tumor Suppressor Gene in Mast Cell Leukemia. *Blood*, **2014**, 124, 1881-1881	2.2	2
111	The Wee1 Inhibitor, MK-1775, Sensitizes Leukemic Cells to Different Antineoplastic Drugs Interfering with DNA Damage Response Pathway. *Blood*, **2015**, 126, 1276-1276	2.2	2
110	The Role of Hypoxic Bone Marrow Microenvironment in Acute Myeloid Leukemia and Future Therapeutic Opportunities. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	2
109	Current treatment approaches in CML.. *HemaSphere*, **2019**, 3,	0.3	2
108	Case Report: A Novel Activating FLT3 Mutation in Acute Myeloid Leukemia. *Frontiers in Oncology*, **2021**, 11, 728613	5.3	2
107	Ponatinib as a Valid Alternative Strategy in Patients with Blast Crisis-Chronic Myeloid Leukemia Not Eligible for Allogeneic Stem Cells Transplantation and/or Conventional Chemotherapy: Report of a Case. *Case Reports in Hematology*, **2017**, 2017, 6167345	0.7	1
106	BCR-ABL1 mutation screening in chronic myeloid leukaemia: is next now?. *Lancet Haematology,the*, **2019**, 6, e236-e237	14.6	1
105	Durable molecular response despite F317L and E255K mutations: Successful treatment of chronic myeloid leukemia with sequential imatinib, nilotinib and dasatinib. *Leukemia Research*, **2012**, 36, e10-1	2.7	1
104	What are the challenges in 2016 regarding resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and cancer?. *Hematological Oncology*, **2017**, 35, 420-423	1.3	1
103	Overcoming Resistance to Kinase Inhibitors: The Paradigm of Chronic Myeloid Leukemia.. *OncoTargets and Therapy*, **2022**, 15, 103-116	4.4	1
102	Next Generation Sequencing-Based BCR-ABL1 Kinase Domain Mutation Screening in De Novo and Tyrosine Kinase Inhibitor-Resistant Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of a Prospective Study. *Blood*, **2018**, 132, 4078-4078	2.2	1
101	Droplet Digital PCR Phasing (DROP-PHASE): A Novel Method for Straightforward Detection of BCR-ABL1 Compound Mutations in Tyrosine Kinase Inhibitors Resistant Chronic Myeloid Leukemia (CML) and Acute Lymphoblastic Leukemia (ALL). *Blood*, **2019**, 134, 4660-4660	2.2	1
100	European Multicenter Experience on Idiopathic Hypereosinophilic Syndrome (HES) with FIP1L1-PDGFRA Rearrangement treated with Imatinib.. *Blood*, **2004**, 104, 1507-1507	2.2	1

99	Better Molecular Response (MR) to Imatinib (IM) in Early Chronic Phase (CP) Versus Late CP Chronic Myeloid Leukemia (CML) Patients (pts) in Complete Cytogenetic Response (CCR): A Comparison at 24 Months of 2 Clinical Trials of the GIMEMA Working Party on CML on Behalf of the GIMEMA Working Party on Chronic Myeloid Leukemia (GIMEMA-CML) . *Blood*, **2005**, 106, 1096-1096	2.2	1
98	The Expression of shp-1 and SHP-2: A Novel Powerful Predictor of Major Molecular Response (MMR) Achievement in Chronic Myeloid Leukemia Gleevec-Treated Patients Enrolled into the TOPS Clinical Trial.. *Blood*, **2008**, 112, 1106-1106	2.2	1
97	High-Resolution Molecular Allelokaryotyping of Chronic Myeloid Leukemia Patients in Blast Crisis by 6.0 SNP-Arrays Shows a High-Frequency of Uniparental Disomy and Focal Copy Number Alterations Affecting the Whole Sequence or Specific Exons of Oncogenes and Tumor Suppressor Genes.. *Blood*, **2009**, 114, 2176-2176	2.2	1
96	Alternating Nilotinib 400 mg twice daily and Imatinib 400 mg once daily as Frontline Treatment of Ph+ Chronic Myeloid Leukemia. A Phase 2 Multicentric Study of the GIMEMA CML Working Party. *Blood*, **2011**, 118, 453-453	2.2	1
95	The Novel Small Molecule Chk1/Chk2 Inhibitor PF-0477736 (Pfizer) Is Highly Active As Single Agent in Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL). *Blood*, **2011**, 118, 76-76	2.2	1
94	Down-Regulation of BMI-1 Is a New Marker of Sensitivity to Mdm2 Inhibition in B-Acute Lymphoblastic Leukemia.. *Blood*, **2012**, 120, 2522-2522	2.2	1
93	Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain Allows Earlier Detection and More Accurate Characterization of Resistant Subclones in Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Receiving Tyrosine Kinase Inhibitor-Based Therapies. *Blood*, **2012**, 120, 284-284	2.2	1
92	Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications. *Blood*, **2012**, 120, 692-692	2.2	1
91	Adult B-Cell Precursor Acute Lymphoblastic Leukemia (BC-ALL) Negative For Recurrent Fusion Genes Are Characterized By a High Complex Genetic Heterogeneity Influencing Prognosis. *Blood*, **2013**, 122, 2622-2622	2.2	1
90	RNA Sequencing Reveals Novel and Rare Fusion Transcripts in Acute Myeloid Leukemia. *Blood*, **2015**, 126, 3627-3627	2.2	1
89	Genome-Wide Molecular Portrait of Aggressive Systemic Mastocytosis and Mast Cell Leukemia Depicted By Whole Exome Sequencing and Copy Number Variation Analysis. *Blood*, **2015**, 126, 4085-4085	2.2	1
88	Impact of Age on Efficacy, Safety, and Long-Term Outcome of Chronic Myeloid Leukemia (CML) Patients Treated in First-Line with Nilotinib: An Analysis of the Gimema CML Working Party. *Blood*, **2016**, 128, 3068-3068	2.2	1
87	Gene Expression Profile in the CML Cell Line K562 Treated with SKI-606, a Dual Inhibitor of Src/Abl Kinase.. *Blood*, **2005**, 106, 4870-4870	2.2	1
86	The Genomic and Transcriptomic Landscape of Systemic Mastocytosis. *Blood*, **2016**, 128, 3136-3136	2.2	1
85	Inotuzumab ozogamicin and donor lymphocyte infusion is a safe and promising combination in relapsed acute lymphoblastic leukemia after allogeneic stem cell transplant. *Hematological Oncology*, **2021**, 39, 580-583	1.3	1
84	Identification of Two Mutations Compromising Protein Stability and Methylation Capacity in Acute Myeloid Leukemia. *Journal of Oncology*, **2019**, 2019, 5985923	4.5	1
83	A Review and an Update of European LeukemiaNet Recommendations for the Management of Chronic Myeloid Leukemia. *Hematologic Malignancies*, **2021**, 145-158	0	1
82	Next-generation sequencing improves BCR-ABL1 mutation detection in Philadelphia chromosome-positive acute lymphoblastic leukaemia. *British Journal of Haematology*, **2021**, 193, 271-279	4.5	1

81	The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report. *BMC Cancer*, **2017**, 17, 523	4.8	0
80	The BCR-ABL Transcript Levels At 3 and 6 Months Predict the Long-Term Outcome of Chronic Myeloid Leukemia Patients Treated Frontline with Imatinib Mesylate: A Gimema CML WP Analysis. *Blood*, **2012**, 120, 1678-1678	2.2	0
79	Long-Term Outcome to First-Line Imatinib according to 2013 European LeukemiaNet Response Criteria: a GIMEMA CML WP Analysis. *Blood*, **2015**, 126, 2792-2792	2.2	0
78	MDM2 and Aurora Kinase a Contribute to SETD2 Loss of Function in Advanced Systemic Mastocytosis: Implications for Pathogenesis and Treatment. *Blood*, **2018**, 132, 1779-1779	2.2	0
77	A Multi-Institutional Retrospective Analysis of Tyrosine Kinase Inhibitor (TKI) Clinical and Preclinical Efficacy According to BCR-ABL Mutation Status in CP-CML Patients. *Blood*, **2015**, 126, 2790-2790	2.2	0
76	BCR-ABL Fusion Transcript Do Not Significantly Influence the Outcome of Chronic Myeloid Leukemia Patients In Early Chronic Phase Treated with Imatinib Mesylate: a GIMEMA CML WP Analysis.. *Blood*, **2010**, 116, 1230-1230	2.2	0
75	Harmonized Testing for BCR-ABL Kinase Domain Mutations In CML: Results of a Survey and First Control Round within 28 National Reference Laboratories In Europe. *Blood*, **2010**, 116, 894-894	2.2	0
74	Ultradeep-Amplicon Pyrosequencing for Mutation Detection in the Kinase Domain of BCR-ABL Revealed Artificial Low-Level Variants That Need to Be Avoided for Relevant Mutational Data Interpretation. *Blood*, **2012**, 120, 1396-1396	2.2	0
73	Improving prognostication and management of systemic mastocytosis. *Lancet Haematology,the*, **2021**, 8, e164-e166	14.6	0
72	Nilotinib against high dose imatinib for salvage therapy of chronic myeloid leukaemia. *Lancet Haematology,the*, **2016**, 3, e554-e555	14.6	
71	Interferon in CML: back to the past, or towards the future?. *Lancet Haematology,the*, **2015**, 2, e8-9	14.6	
70	Imatinib Therapy for Chronic Myeloid Leukemia Patients Who Relapse after Allogeneic Stem Cell Transplantation: A Molecular Analysis.. *Blood*, **2004**, 104, 4655-4655	2.2	
69	Prediction of Response to Imatinib by Prospective Quantitation of BCR-ABL Transcript in Late Chronic Phase Chronic Myeloid Leukemia PatientsBy GIMEMA Working Party on CML.. *Blood*, **2004**, 104, 4672-4672	2.2	
68	Imatinib Mesylate Determines a High Frequency of Major Molecular Responses in Newly Diagnosed Philadelphia Chromosome-Positive Chronic Phase Chronic Myeloid Leukemia (CML) on Behalf of the GIMEMA Working Party on Chronic Myeloid Leukemia (GIMEMA-CML).. *Blood*, **2005**, 106, 1100-1100	2.2	
67	SU11657, a FLT3-Targeted Tyrosine Kinase, Has Pro-Apoptotic Activity on Leukemia Cells In Vitro.. *Blood*, **2005**, 106, 2797-2797	2.2	
66	A Study of the Binding Mode and the In Vitro Activity of the Protein Tyrosine Kinase Inhibitor SKI-606 in the BCR-ABL Positive Cells.. *Blood*, **2006**, 108, 2335-2335	2.2	
65	Direct and Coordinate Regulation of Multidrug Resistance Genes by the c-Myc Oncoprotein.. *Blood*, **2006**, 108, 2594-2594	2.2	
64	Impact of Age in the Outcome of Patients with Chronic Myeloid Leukemia in Late Chronic Phase: Clinical and Molecular Results of a Phase II Study of the GIMEMA CML Working Party.. *Blood*, **2006**, 108, 4805-4805	2.2	

63	The Overexpression of Spliced Oncogenic Ikaros Isoforms in Philadelphia-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients Is a New Mechanism of Resistance to Tyrosine Kinase Inhibitors.. *Blood*, **2007**, 110, 722-722	2.2
62	Aurora Kinase a/MDM2-Mediated SETD2 Loss of Function in Chronic Myeloid Leukemia Patients in Blast Crisis Induces Genetic Instability and Can be Therapeutically Targeted. *Blood*, **2018**, 132, 1726-1726	2.2
61	Biology of Acute Myeloid Leukemia (AML) with Monosomy of Chromosome 7 or Loss of 7q. a Study on 487 Patients Analyzed By Gene Expression Profile (GEP), Single Nucleotide Polymorphism (SNP) Arrays and Metabolomics. *Blood*, **2018**, 132, 2748-2748	2.2
60	DNA Analysis of Mutations in the Kinase Domain of BCR-ABL1 By Allele-Specific Digital PCR Is Highly Sensitive and Refines Prediction of Kinetics of Resistant CML Clones. *Blood*, **2018**, 132, 1743-1743	2.2
59	Higher Expression of PALB2 Predict Poor Prognosis in AML Patients and Identifies Potential Targets of Synthetic Lethal Therapies. *Blood*, **2018**, 132, 1507-1507	2.2
58	PS1437 SETD2 NON-GENOMIC LOSS OF FUNCTION IN ADVANCED SYSTEMIC MASTOCYTOSIS (SM): PATHOGENETIC AND THERAPEUTIC IMPLICATIONS. *HemaSphere*, **2019**, 3, 662-663	0.3
57	In Systemic Masocytosis, Midostaurin Targets Both Kit and Aurora Kinase a Reverting H3K36Me3 Deficiency and Synergizes with Second-Generation Tyrosine Kinase Inhibitors. *Blood*, **2019**, 134, 4204-4204	2.2
56	Aurora Kinase a/MDM2-Mediated SETD2 Loss of Function in Chronic Myeloid Leukemia Patients in Blast Crisis Can be Therapeutically Targeted Inducing Apoptotic Cell Death in a Caspase-Dependent Way. *Blood*, **2019**, 134, 4142-4142	2.2
55	PKC412 (midostaurin) is safe and highly effective in systemic mastocytosis: Follow up of a single-center Italian compassionate use.. *Journal of Clinical Oncology*, **2014**, 32, 7113-7113	2.2
54	Backtracking BCR-ABL1 Mutants in Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Relapsing on Tyrosine Kinase Inhibitors with Deep Sequencing: Implications for Routine Mutation Testing. *Blood*, **2014**, 124, 2259-2259	2.2
53	Ultra-Deep Sequencing (UDS) Allows More Sensitive Detection of the D816V and Other Kit Gene Mutations in Systemic Mastocytosis. *Blood*, **2014**, 124, 1856-1856	2.2
52	Five-Year Outcome of 215 Newly Diagnosed Chronic Myeloid Leukemia Patients Treated Frontline with Nilotinib-Based Regimens: A Gimema CML Working Party Analysis. *Blood*, **2014**, 124, 3141-3141	2.2
51	A Survey on Clinical and Biological Characteristic and Therapy Management of an Italian Series of 455 Adult Patients with Systemic Mastocytosis on Behalf of Italian Registry of Mastocytosis. *Blood*, **2014**, 124, 3188-3188	2.2
50	Two or More Chemotherapy Consolidation Courses, Followed By Autologous Bone Marrow Transplantation, and MRD Negativity, Give Long Term Overall Survival in Acute Myeloid Leukemia Patients. *Blood*, **2015**, 126, 3198-3198	2.2
49	Genomic-Wide Analysis By High Resolution SNP Array Identifies Novel Genomic Alteration in Acute Myeloid Leukemia. *Blood*, **2015**, 126, 2600-2600	2.2
48	Novel Genomic Patterns of Metabolic Remodeling in Acute Myeloid Leukemia. *Blood*, **2015**, 126, 3837-3837	2.2
47	Gemtuzumab-Ozogamicin Containing Regimens As Induction Therapy Give the Highest Complete Remission Rate and the Longest Overall Survival Compared with Other Induction Regimens in Patients with Newly Diagnosed Acute Myeloid Leukemia. *Blood*, **2015**, 126, 2513-2513	2.2
46	Bone Marrow (BM) Microenviroment Factors As Early Markers of Response in Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Treated with Nilotinib. *Blood*, **2015**, 126, 1570-1570	2.2

45	A Specific Pattern of Somatic Mutations Associates with Poor Prognosis Aneuploid Acute Myeloid Leukemia: Results from the European NGS-PTL Consortium. *Blood*, **2015**, 126, 3840-3840	2.2
44	Aurora Kinase a: A New Component of Imatinib Resistance in Chronic Myeloid Leukemia. *Blood*, **2015**, 126, 1573-1573	2.2
43	The Inhibition of Checkpoint Kinase 1 As a Promising Strategy to Increase the Effectiveness of Different Treatments in Acute Lymphoblastic Leukemia. *Blood*, **2015**, 126, 2478-2478	2.2
42	Impact on survival of catastrophic karyotype events in 101 consecutive acute myeloid leukemia (AML) patients: High risk karyotype and chromothripsis.. *Journal of Clinical Oncology*, **2016**, 34, 7044-7044	2.2
41	The 'Next-in-Cml' Study: A Prospective Multicenter Study of Deep Sequencing of the BCR-ABL1 Kinase Domain in Philadelphia Chromosome-Positive Patients with Non-Optimal Responses to Tyrosine Kinase Inhibitor Therapy. *Blood*, **2016**, 128, 3097-3097	2.2
40	Chromothripsis in Acute Myeloid Leukemia Is Strongly Associated with Poor Prognosis and TP53 Alterations. *Blood*, **2016**, 128, 1678-1678	2.2
39	Assessment of BCR-ABL1 Transcript Levels By Digital PCR (dPCR) in CML Patients who Achieved a Deep Molecular Response (DMR: MR4.0, MR4.5 And MR5.0) with Tkis May Improve the Detection of Minimal Residual Disease (MRD) and the Selection of Patients for Treatment Free Remission (TFR). *Blood*, **2016**, 128, 3096-3096	2.2
38	A Population-Based Study of Chronic Myeloid Leukemia Treated with Imatinib in First Line. *Blood*, **2016**, 128, 3076-3076	2.2
37	Alterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML). *Blood*, **2016**, 128, 1679-1679	2.2
36	Identification and Molecular Characterization of Two Recurrent Genomic Deletions (Type A and Type B) on 7p12 in IKZF1 Gene in a Large Cohort of BCR-ABL1-Positive Acute Lymphoblastic Leukemia (ALL): on Behalf of the GIMEMA ALL Working Party. *Blood*, **2008**, 112, 428-428	2.2
35	Different Isoforms of the B-Cell Mutator Activation-Induced Cytidine Deaminase (AID) Are Aberrantly Over-Expressed in BCR-ABL1-Positive Acute Lymphoblastic Leukemia (ALL) Patients and Promote Genetic Instability.. *Blood*, **2008**, 112, 1497-1497	2.2
34	A decreased Level of Shp1 provides an additive survival advantage to the Ph+ Cells of CML Patients and may account for Resistance to Imatinib Treatment. *Blood*, **2008**, 112, 3186-3186	2.2
33	C-Myc Mediated Regulation of Multidrug Resistance Genes in Chronic Myeloid Leukaemia Cd34+ Cell Progenitors.. *Blood*, **2009**, 114, 3252-3252	2.2
32	PAX5 Wild-Type without IKZF1 (Ikaros) Deletion Is Associated with Prolonged Disease-Free Survival and Low Rate of Cumulative Incidence of Relapse in Adult BCR-ABL1-Positive Acute Lymphoblastic Leukemia (ALL): On Behalf of GIMEMA AL Working Party.. *Blood*, **2009**, 114, 12-12	2.2
31	CD34+ obtained from High Sokal Risk Chronic Myeloid Leukemia (CML) Patients (PTS) Expresses Gene Profiles (GEP) Significantly Different From CD34+ Obtained From Low Sokal Risk Patients.. *Blood*, **2009**, 114, 2174-2174	2.2
30	Association Between Imatinib (IM) Transporters and Metabolizing Enzymes Genotype and Response in Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients (Pts) Is Influenced by Ethnicity.. *Blood*, **2009**, 114, 3283-3283	2.2
29	First Line Treatment with Nilotinib 800 Mg Daily Results In Unprecedentedly High Rate of Rapid, Deep and Stable Molecular Responses as Assessed by a High Sensitive Nanofluidic Array for the Detection of Rare Copies of BCR-ABL1 Transcript: Results of a Phase 2 Trial of the GIMEMA CML Working Party. *Blood*, **2010**, 116, 2720-2720	2.2
28	The Inactivation of the Tumor Suppressor Genes CDKN2A/ARF by Genomic Deletions Frequently Occurs and Worsens Prognosis In Adult BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL) Patients. *Blood*, **2010**, 116, 3136-3136	2.2

27	Bcr-Abl Kinase Domain Mutations in Imatinib and in Second-Generation Tyrosine Kinase Inhibitor Eras: Seven Years of Mutation Analysis, a Report by the GIMEMA CML Working Party. *Blood*, **2010**, 116, 2279-2279	2.2
26	Low-Level Bcr-Abl Kinase Domain Mutations Are Very Rare In Chronic Myeloid Leukemia Patients Who Are In Major Molecular Response After 12 Months of First-Line Nilotinib Therapy.. *Blood*, **2010**, 116, 1666-1666	2.2
25	Specific Drug Transporter Genotypes Are Significantly Associated with Increased Rates of Major and Complete Molecular Responses In Newly Diagnosed Chronic Myeloid Leukemia Patients Treated with Imatinib □A TOPS Correlative Substudy. *Blood*, **2010**, 116, 670-670	2.2
24	Whole Transcriptome Resequencing of Paired Diagnosis-Relapse BCR-ABL1-Positive Acute Lymphoblastic Leukemia (ALL) Samples Reveals the Loss of Cell Cycle Regulation as the Main Mechanism Responsible for Leukemia Progression.. *Blood*, **2010**, 116, 1024-1024	2.2
23	Susceptibility to Philadelphia-Positive acute Lymphoblastic Leukemia (ALL) Is Associated with a Germline Polymorphism In the ANRIL (CDKN2BAS) Locus.. *Blood*, **2010**, 116, 1670-1670	2.2
22	Use of a High Sensitive Nanofluidic Array for the Detection of Rare Copies of BCR-ABL1 Transcript In Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (ALL).. *Blood*, **2010**, 116, 1677-1677	2.2
21	The Elevated Expression of FBP1, a Key-Enzyme of Gluconeogenesis Gene, Is Associated to High Sokal Risk In Chronic Myeloid Leukemia Patients.. *Blood*, **2010**, 116, 3399-3399	2.2
20	Evaluation of the GeneXpert Assay for the Monitoring of BCR-ABL Transcript Levels In Chronic Myeloid Leukemia (CML) Patients: Preliminary Results of a Comparison with the Manual and Traditional Manual TaqMan RQ-PCR Assay. *Blood*, **2010**, 116, 4831-4831	2.2
19	Mutation Analysis of BCR-ABL Tyrosine Kinase Domain In New Chronic Phase-Chronic Myeloid Leukemia Patients with Suboptimal Response or Treatment Failure From Imatinib Treatment.. *Blood*, **2010**, 116, 3441-3441	2.2
18	Validation of the New European LeukemiaNet (ELN) Recommendations for Bcr-Abl Kinase Domain Mutation Analysis In Chronic Myeloid Leukemia: An Analysis of the GIMEMA CML Working Party Studies. *Blood*, **2011**, 118, 112-112	2.2
17	Drug Resistance and Bcr-Abl Kinase Domain Mutations In Philadelphia-Positive Acute Lymphoblastic Leukemia From the Imatinib to the 2nd-Generation Tyrosine Kinase Inhibitor Era: The Main Changes Are In the Type of Mutations, but Not In the Frequency of Mutation Involvement. *Blood*, **2011**, 118, 575-575	2.2
16	Long Term Follow-up of Ph+ CML Patients Achieving Complete Cytogenetic Response (CCgR) with Interferon Based Therapy - GIMEMA Protocol CML0509. *Blood*, **2011**, 118, 786-786	2.2
15	TP53 Alterations Including Missense Mutations, Aberrant Exon-Junctions and Internal Intron Retentions Are Frequent and May Contribute to MDM2 Antagonist-Resistance in B-Acute Lymphoblastic leukemia. *Blood*, **2011**, 118, 1484-1484	2.2
14	ARF Loss, a Negative Prognostic Factor in Philadelphia-Positive Acute Lymphoblastic Leukemia, May Be Efficiently Overcome by the Small Molecule MDM2 Antagonist RG7112. *Blood*, **2011**, 118, 2574-2574	2.2
13	Ultra-Deep Amplicon Sequencing Using Roche 454 Technology Allows High Sensitivity Bcr-Abl Kinase Domain Mutation Screening and Anticipates Emerging Mutations Leading to Resistance to Tyrosine Kinase Inhibitors in Philadelphia-Positive Leukemia Patients,. *Blood*, **2011**, 118, 3775-3775	2.2
12	Improved Detection of the KIT D816V Mutation Using a Real-Time PCR Assay Allows a Finer Recognition of Patients with Indolent Systemic Mastocytosis. *Blood*, **2011**, 118, 5163-5163	2.2
11	PKC412 (Midostaurin) Is Safe and Highly Effective in Systemic Mastocytosis Patients: The Bologna Experience. *Blood*, **2012**, 120, 1749-1749	2.2
10	Loss of Heterozygosity At the C Wild-Type Allele of rs1042522 in the TP53 Gene Frequently Occurs During Progression of Adult BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL).. *Blood*, **2012**, 120, 2497-2497	2.2

9	Cytogenetic and Molecular Responses At 3 Months Are Associated with A Better Outcome in Early Chronic Phase (ECP) Chronic Myeloid Leukemia (CML) Patients Treated with Nilotinib.. *Blood*, **2012**, 120, 2797-2797	2.2
8	Algorithms and Processing Pipeline For Error Correction and Detection Of Significant Mutations In The Kinase Domain Of BCR-ABL Analyzed By Next-Generation Sequencing: Implications For Clinical Practice Of Chronic Myeloid Leukemia. *Blood*, **2013**, 122, 3987-3987	2.2
7	The e13a2 BCR-ABL1 Fusion Transcript Is a Candidate Adverse Prognostic Factor In Chronic Myeloid Leukemia Patients Treated Frontline With Imatinib Mesylate. *Blood*, **2013**, 122, 1486-1486	2.2
6	4-Year Outcome Of 215 Patients With Newly Diagnosed Chronic Myeloid Leukemia (CML) Treated Frontline With Nilotinib In Investigator-Sponsored Studies. A Report From The Gimema CML Working Party. *Blood*, **2013**, 122, 4000-4000	2.2
5	Ponatinib Is Well Tolerated and Active In Patients With Relapsed/Refractory Philadelphia Positive Acute Lymphoblastic Leukemia (PH+ ALL) and Advanced Phase Of Chronic Myelogenous Leukemia (CML) Harbouring T315I Mutation: The Bologna Experience. *Blood*, **2013**, 122, 3911-3911	2.2
4	Minor Subclones Harboring Small Insertions and Deletions Probably Due To Aberrant Splicing Can Frequently Be Detected By Deep Sequencing of The BCR-ABL Kinase Domain. *Blood*, **2013**, 122, 3986-3986	2.2
3	Coexistence of inversion 16 in chronic myeloid leukaemia in blast crisis. *Journal of Hematopathology* , **2016**, 9, 155-160	0.4
2	PF172 PROSPECTIVE COMPARISON OF SANGER SEQUENCING VS NEXT GENERATION SEQUENCING FOR ROUTINE BCR-ABL1 KINASE DOMAIN MUTATION SCREENING IN PHILADELPHIA-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS. *HemaSphere*, **2019**, 3, 37-38	0.3
1	Molecular Testing of CML Patients in 2021: Between Old and New Tools. *Clinical Lymphoma, Myeloma and Leukemia*, **2021**, 21, S63-S65	2